Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression

mAbs

Volumn 5, Issue 2, 2013, Pages 255-262

  Buchanan, Andrew ^a   Clementel, Veronica ^a   Woods, Rob ^a   Harn, Nicholas ^a   Bowen, Michael A ^a   Mo, Wenjun ^a   Popovic, Bojana ^a   Bishop, Steven M ^a   Dall'Acqua, William ^a   Minter, Ralph ^a   Jermutus, Lutz ^a   Bedian, Vahe ^b  

^a MEDIMMUNE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Aggregation; Antibody; Cysteinylation; Expression; Stability

Indexed keywords

ANGIOPOIETIN 2; CYSTEINE; IMMUNOGLOBULIN G;

ANTIBODY ENGINEERING; ARTICLE; CANCER PATIENT; HUMAN; IMMUNOGENICITY; MASS SPECTROMETRY; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STABILITY; THERMOSTABILITY;

AGGREGATION; ANTIBODY; CYSTEINYLATION; EXPRESSION; STABILITY;

ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL; CYSTEINE; HOT TEMPERATURE; HUMANS; IMMUNOGLOBULIN G; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PROTEIN ENGINEERING; PROTEIN STABILITY;

EID: 84876563164     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.23392     Document Type: Article

References (44)

1. Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol 2006; 3: 123-30; PMID:18958692; http://dx.doi.org/10.1080/15476910600845567
2. Pointreau Y, Commins SP, Calais G, Watier H, Platts- Mills TA. Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis. J Clin Oncol 2012; 30:334, author reply 335; PMID:22162592; http://dx.doi.org/ 10.1200/JCO.2011.38.4701
3. Bender NK, Heilig CE, Dröll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007; 27: 269-74; PMID:17006705; http://dx.doi.org/10.1007/s00296- 006-0183-7
4. Anonymous. International conference on harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/ biological products. Notice Food and Drug Administration HHS Fed Regist 1999; 64: 44928-35
5. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011; 84: 41-61; PMID:21846562; http://dx.doi.org/10. 1016/B978-0-12-386483-3.00004-5
6. Aucamp JP, Cosme AM, Lye GJ, Dalby PA. Highthroughput measurement of protein stability in microtiter plates. Biotechnol Bioeng 2005; 89: 599-607; PMID:15672379; http://dx.doi.org/10.1002/ bit.20397
7. Garidel P, Hegyi M, Bassarab S, Weichel M. A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy. Biotechnol J 2008; 3: 1201-11; PMID:18702089; http://dx.doi.org/10.1002/biot.200800091
8. Goldberg DS, Bishop SM, Shah AU, Sathish HA. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: Role of conformational and colloidal stability. J Pharm Sci 2010; 100: 1306-15; PMID:20960568; http://dx.doi.org/10.1002/ jps.22371
9. Conley GP, Viswanathan M, Hou Y, Rank DL, Lindberg AP, Cramer SM, et al. Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability. Biotechnol Bioeng 2011; 108: 2634-44; PMID:21618474; http://dx.doi.org/10.1002/bit.23220
10. Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 2012; 101: 102-15; PMID:21935950; http://dx.doi.org/10.1002/jps.22758
11. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol 2009; 27: 26-34; PMID:19131992; http://dx.doi.org/10.1038/ nbt0109-26
12. Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, et al. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 2012; 40: 1321-30; PMID:22327175
13. MedImmune LLC. Phase 1/1b, open-label, dose-escalation and expansion study to evaluate the safety and antitumor activity of MEDI3617 as a single-agent or in combination therapy in adult subjects with advanced solid tumors. ClinicalTrials.gov Identifier: NCT01248949
14. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27: 767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt.1553
15. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 2010; 19: 954-66; PMID:20198683
16. Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, et al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs 2010; 21: 907-16; PMID:20847643; http://dx.doi.org/10.1097/ CAD.0b013e32833f5d68
17. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, et al. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A 2012; 109: 10879-84; PMID:22745168; http://dx.doi.org/10.1073/pnas.1202866109
18. Jespers L, Schon O, Famm K, Winter G. Aggregationresistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 2004; 22: 1161-5; PMID:15300256; http://dx.doi.org/10.1038/nbt1000
19. Christ D, Famm K, Winter G. Repertoires of aggregation- resistant human antibody domains. Protein Eng Des Sel 2007; 20: 413-6; PMID:17720749; http://dx.doi.org/10.1093/protein/gzm037
20. Woo HJ, Lotz MM, Jung JU, Mercurio AM. Carbohydrate-binding protein 35 (Mac-2), a laminin- binding lectin, forms functional dimers using cysteine 186. J Biol Chem 1991; 266: 18419-22; PMID:1917966
21. Wootton SK, Yoo D. Homo-oligomerization of the porcine reproductive and respiratory syndrome virus nucleocapsid protein and the role of disulfide linkages. J Virol 2003; 77: 4546-57; PMID:12663761; http://dx.doi.org/10.1128/ JVI.77.8.4546-4557.2003
22. Trivedi MV, Laurence JS, Siahaan TJ. The role of thiols and disulfides on protein stability. Curr Protein Pept Sci 2009; 10: 614-25; PMID:19538140; http://dx.doi.org/10.2174/138920309789630534
23. Lacy ER, Baker M, Brigham-Burke M. Free sulfhydryl measurement as an indicator of antibody stability. Anal Biochem 2008; 382: 66-8; PMID:18675772; http://dx.doi.org/10.1016/j.ab.2008.07.016
24. Gadgil HS, Bondarenko PV, Pipes GD, Dillon TM, Banks D, Abel J, et al. Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC/MS analysis. Anal Biochem 2006; 355: 165-74; PMID:16828048; http://dx.doi.org/10.1016/j.ab.2006.05.037
25. Kroon DJ, Baldwin-Ferro A, Lalan P. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 1992; 9: 1386-93; PMID:1475223; http://dx.doi.org/10.1023/A:1015894409623
26. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176: 1215-24; PMID:9359721; http://dx.doi.org/10.1086/514115
27. Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008; 317: 103-23; PMID:17990791; http://dx.doi.org/10.1007/ 978-3- 540-72146-8-4
28. Liu H, Gaza-Bulseco G, Sun J. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 837: 35-43; PMID:16644295; http://dx.doi.org/10.1016/j.jchromb.2006.03.053
29. Banks DD, Gadgil HS, Pipes GP, Bondarenko PV, Hobbs V, Scavezze JL, et al. Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recomninant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity. J Pharm Sci 2008; 97: 775-90. PMID: 17786988
30. Stimmel JB, Merrill BM, Kuyper LF, Moxham CP, Hutchins JT, Fling ME, et al. Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies. J Biol Chem 2000; 275: 30445-50; PMID:10880507; http://dx.doi.org/ 10.1074/jbc. M001672200
31. Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, Vandlen R, et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods 2008; 332: 41-52; PMID:18230399; http://dx.doi.org/10.1016/j. jim.2007.12.011
32. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26: 925-32; PMID:18641636; http://dx.doi.org/10.1038/nbt.1480
33. Voynov V, Chennamsetty N, Kayser V, Wallny HJ, Helk B, Trout BL. Design and application of antibody cysteine variants. Bioconjug Chem 2010; 21: 385-92; PMID:20092294; http://dx.doi.org/10.1021/ bc900509s
34. Cordoba-Rodriguez RV. Aggregates in MAbs and recombinant therapeutic proteins: a regulatory perspective. BioPharm Int 2008; 21: 44-53
35. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. Classification and characterization of therapeutic antibody aggregates. J Biol Chem 2011; 286: 25118-33; PMID:21454532; http://dx.doi.org/10.1074/jbc.M110.160457
36. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res 2010; 27: 544-75; PMID:20143256; http://dx.doi.org/10.1007/s11095- 009-0045-6
37. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc MP, et al. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007; 64: 210-25; PMID:17624800; http://dx.doi.org/10.1016/j.critrevonc.2007.04. 011
38. Ehrenmann F, Kaas Q, Lefranc MP. IMGT/3Dstructure- DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF. Nucleic Acids Res 2010; 38(Database issue):D301-7; PMID:19900967; http://dx.doi.org/10.1093/nar/gkp946
39. Pommié C, Levadoux S, Sabatier R, Lefranc G, Lefranc MP. IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties. J Mol Recognit 2004; 17: 17-32; PMID:14872534; http://dx.doi.org/10.1002/jmr.647
40. Franey H, Brych SR, Kolvenbach CG, Rajan RS. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates. Protein Sci 2010; 19: 1601-15; PMID:20556807; http://dx.doi.org/10.1002/pro.434
41. Liu YD, Chen X, Enk JZ, Plant M, Dillon TM, Flynn GC. Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 2008; 283: 29266-72; PMID:18713741; http://dx.doi.org/10.1074/jbc. M804787200
42. Ju G, Collins L, Kaffka KL, Tsien WH, Chizzonite R, Crowl R, et al. Structure-function analysis of human interleukin-2. Identification of amino acid residues required for biological activity. J Biol Chem 1987; 262: 5723-31; PMID:3106342
43. Raso SW, Abel J, Barnes JM, Maloney KM, Pipes G, Treuheit MJ, et al. Aggregation of granulocyte-colony stimulating factor in vitro involves a conformationally altered monomeric state. Protein Sci 2005; 14: 2246-57; PMID:16131655; http://dx.doi.org/10.1110/ ps.051489405
44. Van Walle I, Gansemans Y, Parren PWHI, Stas P, Lasters I. Immunogenicity screening in protein drug development. Expert Opin Biol Ther 2007; 7: 405-18; PMID:17309332; http://dx.doi.org/10.1517/14712598.7.3.405